CareDx (CDNA) Stock Climbs On Q3 Earnings And Expanding Margins

CareDx came into this Q3 2026 report with a stock that had already been on a tear over the past quarter, and then the latest print lit a fresh fire. The share price jumped 22.2% on the day to US$87.41, a reaction that tells you investors saw something far more encouraging than a routine quarter.

The real headline is in the transplant and oncology testing engine. Revenue reached US$139.4 million while adjusted EBITDA hit US$30 million, a 22% margin that underlines how this diagnostics platform is scaling. That gap between a euphoric chart and hard earnings quality is what you now need to weigh.

Love CareDx's revenue engine and 22% EBITDA margin but want peers with the same earnings power and balance sheet strength? Scan our list of solid balance sheet and fundamentals stocks (25 results).

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs Q3 2025): US$139.4 million vs. US$100.1 million (approximately 39% higher)
• Net Income, Excl. Extra Items (Q3 2026 vs Q3 2025): US$19.3 million vs. US$1.7 million (very large increase)
• Basic EPS (Q3 2026 vs Q3 2025): US$0.37 vs. US$0.03 (very large increase)
• Adjusted EBITDA Margin (Q3 2026 vs Q3 2025): 22% vs. approximately 11% (margin roughly doubled)

CareDx is guiding years ahead on AlloHeme revenue and coverage. Ask Charlie what makes CareDx’s AlloHeme timeline so unusual.

CareDx Bull Case Meets Concrete Integration Milestones

The bullish pitch hinges on CareDx turning portfolio reshaping into durable high margin testing scale.

"An important factor for this thesis is continued execution on integrating Naveris and NavDx, commercializing AlloHeme, and embedding CareDx assays into routine clinical workflows with stable reimbursement."

Q3 shows that integration is not just a slide. NavDx contributed US$12.5 million of oncology testing revenue with roughly 15,000 tests and an average selling price near US$823. Management has already migrated NavDx billing in house and is targeting Epic ordering by early 2027. AlloHeme and HistoMap Kidney both reached CLIA readiness milestones, keeping commercialization timetables intact and supporting the volume driven thesis.

One Narrative has put a figure on that disagreement. → See the Narrative with its lower Fair Value, assumptions and all.

CareDx Bear Case: Execution Risks Still Unresolved

Bearish investors worry CareDx will struggle to turn its pipeline into fully adopted, reimbursed franchises rather than slideware. One specific concern centers on oncology and cell therapy execution.

"While AlloHeme and other cell therapy and oncology programs such as AML and MDS relapse monitoring aim to extend CareDx’s repeat testing model into new areas following encouraging trial data and planned launch timelines, delays in CLIA readiness, coverage decisions or slower physician adoption would reduce the expected future contribution to revenue diversification and could result in earnings falling short of what the current P/E multiple suggests."

Q3 kept AlloHeme and HistoMap Kidney on track for CLIA readiness by year end, yet there is still no 2026 revenue or payer coverage. Near term oncology contribution rests almost entirely on NavDx, so the diversification story remains incomplete and exposure to future launch or reimbursement slippage is intact.

Hunt For Mispriced Earnings Power

CareDx recently reminded investors how sentiment can shift when operational delivery supports a clear earnings narrative. The real opportunity is identifying stocks that could be undervalued before new information reshapes how the market views their earnings power.

• Company 1 - 35% below our estimate - sells accelerated computing racks as data centre operators accommodate expanding AI workloads.
• Company 2 - 19% below our estimate - grows a teahouse network as overseas outlets and memberships influence franchise and store economics.
• Company 3 - 46% below our estimate - supplies large LED display systems as venues and transport projects replace static signs with digital screens.

Those are three of them. See every one of the 29 undervalued companies on it →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com